Date & Time: August 14-15, 2018. ObsEva will present on Tuedsday August 14th 2018 at 8.00am Eastern Time (ET) Location: New York…
Category: Content
This category defines content that can be used throughout the website. So for example an article, a report, a file,… i.e. a press release can be displayed on the “press release” page but the newest press release is also displayed on the homepage.
ObsEva SA to Participate in Wedbush PacGrow Healthcare Conference August 14-15, 2018
Geneva, Switzerland and Boston, MA – August 10, 2018 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and…
Half-Year Report 2018
ObsEva Reports Second Quarter 2018 Financial Results and Provides Business Update
Phase 2b EDELWEISS clinical trial of linzagolix (OBE2109) in endometriosis related pelvic pain achieved primary and secondary endpoints Chief Commercial…
Q2 2018 ObsEva SA Earnings Conference Call
Investors may participate by dialing (844) 419-1772 for U.S. callers and +1 (213) 660-0921 for international callers, and referring to…
ObsEva SA to Hold Second Quarter 2018 Financial Results and Business Update Call on August 8, 2018
Geneva, Switzerland and Boston, MA – July 31, 2018– ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and…
ObsEva Expands Executive Team Hiring a Chief Commercial Officer
Geneva, Switzerland and Boston, MA – July 25, 2018– ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and…
ObsEva SA to start trading today on the SIX Swiss Exchange
Trading of ObsEva’s shares on SIX Swiss Exchange starts under the ticker symbol ‘OBSN’ Reference price at CHF 15.00 per share ObsEva with unique…
SIX Listing
ObsEva SA Shares to Begin Trading on SIX Swiss Exchange
Listing of 45’381’252 registered shares with a par value of 1/13 of CHF 1 per share Anticipated market capitalisation of more…